Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Henri Bounameaux
  • Sylvia Haas
  • Alfredo E Farjat
  • Walter Ageno
  • Jeffrey I Weitz
  • Samuel Z Goldhaber
  • Alexander G G Turpie
  • Shinya Goto
  • Pantep Angchaisuksiri
  • Joern Dalsgaard Nielsen
  • Gloria Kayani
  • Sebastian Schellong
  • Lorenzo G Mantovani
  • Paolo Prandoni
  • Ajay K Kakkar
Vis graf over relationer

INTRODUCTION: Randomized controlled trials have shown that direct oral anticoagulants (DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). However, there are limited post-marketing data describing the effectiveness and safety of the DOACs in the community setting. We aimed to compare the effectiveness of DOACs and VKAs on 12-month outcomes in a real-world VTE patient population.

METHODS: The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE is an observational study designed to document real-world treatment practices. This intention-to-treat analysis included 7987 VTE patients initiated on either DOACs (N = 4791) or VKAs (N = 3196) with or without pre-treatment with parenteral anticoagulants. Treatment groups were balanced according to baseline characteristics, using overlapping propensity score weights.

RESULTS: After adjustment for baseline characteristics, all-cause mortality was significantly lower with DOAC than with VKAs (hazard ratio [HR]: 0.73; 95% confidence interval [CI] 0.56-0.95. Patients receiving VKAs were more likely than those receiving DOACs to die of complications of VTE (4.7% vs 2.7%) or from bleeding (4.2% vs. 1.3%). There was no significant difference in recurrent VTE (HR: 0.91, 95% CI 0.71-1.18), major bleeding (HR 1.03, 95% CI 0.69-1.54), or overall bleeding (HR 0.96, 95% CI 0.81-1.14) with DOACs or VKAs.

CONCLUSIONS: n this real-world analysis of VTE treatment, DOACs were associated with reduced all-cause mortality compared with VKAs, and similar rates of recurrent VTE and bleeding.

OriginalsprogEngelsk
TidsskriftThrombosis Research
Vol/bind191
Sider (fra-til)103-112
Antal sider10
ISSN0049-3848
DOI
StatusUdgivet - jul. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 61765857